JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis
Myelofibrosis (MF) is a myeloproliferative neoplasm hallmarked by uncontrolled blood counts, constitutional symptoms, extramedullary hematopoiesis, and an increased risk of developing acute myeloid leukemia. Janus kinase (JAK) inhibitors are the most common treatment for MF due to their ability to r...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Innovative Healthcare Institute
2021-08-01
|
| Series: | Journal of Immunotherapy and Precision Oncology |
| Subjects: | |
| Online Access: | https://jipo.org/doi/pdf/10.36401/JIPO-20-36 |
| _version_ | 1797962796985483264 |
|---|---|
| author | Andrew T. Kuykendall Rami S. Komrokji |
| author_facet | Andrew T. Kuykendall Rami S. Komrokji |
| author_sort | Andrew T. Kuykendall |
| collection | DOAJ |
| description | Myelofibrosis (MF) is a myeloproliferative neoplasm hallmarked by uncontrolled blood counts, constitutional symptoms, extramedullary hematopoiesis, and an increased risk of developing acute myeloid leukemia. Janus kinase (JAK) inhibitors are the most common treatment for MF due to their ability to reduce spleen size and improve disease-related symptoms; however, JAK inhibitors are not suitable for every patient and their impact on MF is limited in several respects. Novel JAK inhibitors and JAK inhibitor combinations are emerging that aim to enhance the treatment landscape, providing deeper responses to a broader population of patients with the continued hope of providing disease modification and improving long-term outcomes. In this review, we highlight several specific areas of unmet need within MF. Subsequently, we review agents that target those areas of unmet need, focusing specifically on the JAK inhibitors, momelotinib, pacritinib, itacitinib, and NS-018 as well as JAK inhibitor combination approaches using CPI-0610, navitoclax, parsaclisib, and luspatercept. |
| first_indexed | 2024-04-11T01:18:27Z |
| format | Article |
| id | doaj.art-6a47315a1958433da9df83ec4dfd7d1c |
| institution | Directory Open Access Journal |
| issn | 2666-2345 2590-017X |
| language | English |
| last_indexed | 2024-04-11T01:18:27Z |
| publishDate | 2021-08-01 |
| publisher | Innovative Healthcare Institute |
| record_format | Article |
| series | Journal of Immunotherapy and Precision Oncology |
| spelling | doaj.art-6a47315a1958433da9df83ec4dfd7d1c2023-01-03T16:42:10ZengInnovative Healthcare InstituteJournal of Immunotherapy and Precision Oncology2666-23452590-017X2021-08-0112914110.36401/JIPO-20-36i2590-017X-4-3-129JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with MyelofibrosisAndrew T. KuykendallRami S. KomrokjiMyelofibrosis (MF) is a myeloproliferative neoplasm hallmarked by uncontrolled blood counts, constitutional symptoms, extramedullary hematopoiesis, and an increased risk of developing acute myeloid leukemia. Janus kinase (JAK) inhibitors are the most common treatment for MF due to their ability to reduce spleen size and improve disease-related symptoms; however, JAK inhibitors are not suitable for every patient and their impact on MF is limited in several respects. Novel JAK inhibitors and JAK inhibitor combinations are emerging that aim to enhance the treatment landscape, providing deeper responses to a broader population of patients with the continued hope of providing disease modification and improving long-term outcomes. In this review, we highlight several specific areas of unmet need within MF. Subsequently, we review agents that target those areas of unmet need, focusing specifically on the JAK inhibitors, momelotinib, pacritinib, itacitinib, and NS-018 as well as JAK inhibitor combination approaches using CPI-0610, navitoclax, parsaclisib, and luspatercept.https://jipo.org/doi/pdf/10.36401/JIPO-20-36jak inhibitormyelofibrosismyeloproliferative neoplasmrare disease |
| spellingShingle | Andrew T. Kuykendall Rami S. Komrokji JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis Journal of Immunotherapy and Precision Oncology jak inhibitor myelofibrosis myeloproliferative neoplasm rare disease |
| title | JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis |
| title_full | JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis |
| title_fullStr | JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis |
| title_full_unstemmed | JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis |
| title_short | JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis |
| title_sort | jak be nimble reviewing the development of jak inhibitors and jak inhibitor combinations for special populations of patients with myelofibrosis |
| topic | jak inhibitor myelofibrosis myeloproliferative neoplasm rare disease |
| url | https://jipo.org/doi/pdf/10.36401/JIPO-20-36 |
| work_keys_str_mv | AT andrewtkuykendall jakbenimblereviewingthedevelopmentofjakinhibitorsandjakinhibitorcombinationsforspecialpopulationsofpatientswithmyelofibrosis AT ramiskomrokji jakbenimblereviewingthedevelopmentofjakinhibitorsandjakinhibitorcombinationsforspecialpopulationsofpatientswithmyelofibrosis |